GALNT9

Across TCGA pan-cancer cohorts, GALNT9 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GALNT9 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GALNT9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALNT9 expression acts as an unfavorable survival marker.

PDAC are the cancer types where GALNT9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.238	0.549	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

GALNT9–PDAC (DFS)

Open the PDAC breakdown →